What is Carmat?
Founded in 2008, Carmat is at the forefront of developing innovative solutions for end-stage heart failure. The company's core focus lies in creating advanced artificial heart technology designed to address both chronic and acute forms of this critical condition, which represents a significant global public health challenge and a leading cause of mortality. With a presence spanning Europe, North America, and Asia, Carmat integrates extensive medical expertise with cutting-edge engineering to produce life-saving cardiac devices. The company transitioned to a public entity in 2019, reinforcing its commitment to advancing viable treatment options for individuals suffering from severe heart ailments.
How much funding has Carmat raised?
Carmat has raised a total of $25.9M across 2 funding rounds:
Other Financing Round
$18.6M
Other Financing Round
$7.4M
Other Financing Round (2022): $18.6M with participation from EIC Accelerator
Other Financing Round (2023): $7.4M led by Sante Technology Holdings
Key Investors in Carmat
EIC Accelerator
The EIC Accelerator is a European funding program that supports groundbreaking innovations from SMEs and startups. It provides grants and investment opportunities for high-potential companies developing disruptive technologies.
Sante Technology Holdings
Sante Technology Holdings Inc. is a diversified company involved in building materials. While its primary focus is not in medical devices, its investment in Carmat suggests a strategic interest in the healthcare sector or a broader investment portfolio diversification.
Undisclosed Investor
An undisclosed investor participated in this funding round, indicating a strategic interest in Carmat's innovative artificial heart technology and its market potential.
What's next for Carmat?
The recent major strategic investment in Carmat signals a pivotal phase for the company, likely enabling accelerated research and development, expanded clinical trials, and broader market penetration for its artificial heart technology. This enterprise-level backing suggests confidence from investors in Carmat's potential to address a critical unmet need in cardiovascular medicine. Future strategic initiatives may include further technological advancements, regulatory approvals in key markets, and potential partnerships to enhance global distribution and patient access to these life-saving devices.
See full Carmat company page
